By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celgene International Sárl 

Route de Perreux 1

Boudry    2017  Switzerland
Phone: 41-32-729-85-00 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Celgene International Sárl (CELG) Release: ABRAXANE Approved By European Commission For First-Line Treatment Of Patients With Non-Small Cell Lung Cancer 3/2/2015 10:25:05 AM
Celgene International Sárl (CELG) Release: ABRAXANE Now Reimbursed In Italy As A First-Line Treatment Of Adult Patients With Metastatic Pancreatic Cancer 2/24/2015 11:27:15 AM
Celgene International Sárl (CELG) Release: REVLIMID (Lenalidomide) Approved By European Commission (EC) For The Treatment Of Adult Patients With Previously Untreated Multiple Myeloma Who Are Not Eligible For Transplant 2/23/2015 11:47:46 AM
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Approved By The European Commission For The Treatment Of Both Patients With Psoriasis And Psoriatic Arthritis 1/16/2015 10:16:59 AM
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014 7:37:02 AM
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014 7:35:24 AM
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014 8:34:27 AM
Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association 6/16/2014 10:46:25 AM
Celgene International Sárl (CELG) Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA 6/16/2014 10:44:12 AM
Celgene International Sárl (CELG) Release: First-Of-Its-Kind Multinational Survey Confirms Psoriasis And Psoriatic Arthritis Patients Are Frequently Undertreated Or Not Treated At All 3/20/2014 10:07:58 AM
12345678910...
//-->